George Medicines reports data from two Phase III hypertension treatment trials
George Medicines has reported outcomes from two Phase III clinical trials of GMRx2, a hypertension treatment. GMRx2 is a new triple combination pill that combines telmisartan, amlodipine, and indapamide in ultra-low and low-dose formulations. The first …